ACM
REGN icon

ADAR1 Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

ADAR1 Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.8M Buy
22,208
+10,054
+83% +$6.84M 0.63% 37
2026
Q1 		$9.39M Buy
12,154
+103
+0.9% +$78.9K 0.55% 47
2025
Q4 		$9.3M Sell
12,051
-3,649
-23% -$2.48M 0.68% 36
2025
Q3 		$8.83M Buy
15,700
+12,339
+367% +$6.98M 0.83% 27
2025
Q2 		$1.76M Buy
3,361
+2,000
+147% +$1.12M 0.27% 60
2025
Q1 		$863K Hold
1,361
– – 0.16% 85
2024
Q4 		$969K Buy
1,361
+490
+56% +$411K 0.19% 79
2024
Q3 		$916K Buy
+871
New +$969K 0.15% 83
2024
Q2 		– Sell
-2,300
Closed -$2.21M – 308
2024
Q1 		$2.21M Buy
+2,300
New +$2.19M 0.5% 38

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

ADAR1 Capital Management's REGN Position: Q2 2026 in Review

ADAR1 Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 83% in Q2 2026, buying an estimated $6.84M and bringing the position to 22,208 shares worth $13.8M. The position accounts for 0.63% of the portfolio, ranked #37.

ADAR1 Capital Management first reported a position in REGN in Q1 2024 and has held it in 9 quarters since. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • ADAR1 Capital Management held 22,208 shares of Regeneron Pharmaceuticals worth $13.8M as of Q2 2026.
  • ADAR1 Capital Management bought 10,054 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $6.84M.
  • Regeneron Pharmaceuticals made up 0.63% of ADAR1 Capital Management's portfolio in Q2 2026, its #37 holding.
  • ADAR1 Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.